J.P. Morgan discloses share dealings in Kangji Medical amid privatization

J.P. Morgan Securities PLC, an associate connected with the offeror, disclosed multiple share dealings in Kangji Medical Holdings Limited on September 12, 2025. These dealings, made for J.P. Morgan's own account and ultimately owned by JPMorgan Chase & Co., involved the purchase of shares as part of hedging Delta 1 products from wholly unsolicited client-driven orders.

The disclosed transactions include a purchase of 180,000 shares for a total of $1,602,457.11, with prices ranging from a high of $8.91 to a low of $8.86. Additionally, J.P. Morgan acquired 660,000 shares totaling $5,869,578 at a uniform price of $8.8933.

A further purchase of 500,000 shares was reported, amounting to $4,419,195, with all shares purchased at $8.8296. These disclosures were made pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers, reflecting activities during the company's privatization by way of a scheme of arrangement.